Lean body mass increase and fat loss — body recomposition
A 12-week double-blind RCT in overweight men (n=30) confirmed ForsLean® (250 mg twice daily) significantly increased lean body mass (+4.5 kg), reduced fat mass (−4.7 kg), and improved bone mineral density vs. placebo — achieving body recomposition without caloric restriction. A separate study in overweight women confirmed fat prevention properties, with ForsLean® preventing fat gain during the study period vs. the placebo group.
Metabolic rate and thyroid function support
Elevated cAMP from forskolin activates thyroid stimulating hormone (TSH) receptor signaling, increasing T3 and T4 thyroid hormone production. Higher thyroid hormone levels increase basal metabolic rate, fat oxidation, and thermogenesis — providing a hormonal metabolic boost that complements the direct fat cell lipolysis activation from elevated adipocyte cAMP.
Testosterone support in men
The ForsLean® RCT in overweight men confirmed significant free testosterone elevation (+16.77% vs. +4.5% for placebo) — attributed to cAMP-mediated activation of steroidogenic enzymes in Leydig cells. This testosterone increase, combined with the body composition improvements, makes ForsLean® one of the few natural ingredients with simultaneous fat loss, lean mass, and testosterone evidence.
Adenylyl cyclase activation and cAMP-mediated lipolysis
Forskolin directly activates transmembrane adenylyl cyclase enzyme, converting ATP to cyclic AMP (cAMP) in multiple cell types. In adipocytes, elevated cAMP activates hormone-sensitive lipase (HSL) through PKA phosphorylation — releasing stored triglycerides as free fatty acids for oxidation. In thyroid cells, cAMP activates TSH receptor signaling to increase thyroid hormone synthesis. In Leydig cells, cAMP activates steroidogenic acute regulatory protein (StAR) for testosterone biosynthesis. This simultaneous multi-tissue cAMP activation explains ForsLean®'s concurrent effects on fat loss, metabolism, and testosterone.
Randomized, double-blind, placebo-controlled trial of ForsLean® (250 mg twice daily) in 30 overweight men over 12 weeks. Published in Obesity Research.
30 overweight men. 12-week RCT.
ForsLean® significantly increased lean body mass (+4.5 kg), reduced fat mass (−4.7 kg), and improved bone mineral density vs. placebo. Free testosterone increased 16.77% vs. 4.5% placebo. Metabolic rate markers improved. Confirms ForsLean® for genuine body recomposition.